In a joint effort to tackle #Alzheimer, TechnoPhage S.A. in collaboration with ICNAS is developing a diagnostic solution in #PET imaging for this overwhelming pathology. This project is a result from a partnership with Grupo #Medinfar and #Recipharm Venture Fund.

TechnoPhage S.A. announces #FDA Fast Track Designation Granted to TP-102 for the treatment of patients with infected #diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii

In this International Clinical Trials Day we recognize all the people conducting clinical trials, and we celebrate their hard work promoting clinical research. #clinicaltrialsday #CTD2021

TechnoPhage S.A. is hiring a Laboratory Technician to support research activities and conduct laboratory experiments within a team dedicated to the R&D of new biologic medicines. To learn more about this position follow the link 👇 technophage.pt/technophage-is…

Raquel arrived at #Technophage more than a decade ago, fresh from college. She is now a brilliant senior scientist in charge of different #research projects in the Infection therapeutic area, taking the projects from early discovery into #preclinical studies. #MeetTheTeam

TechnoPhage S.A.'s CEO, Miguel Garcia, attended the "Encontro Ciência 2021" in the last 30 of June, speaking about the company's journey at the plenary session "A ciência cura: desafios e oportunidades da interação ciência-saúde". #ciencia2021PT #technophage

TechnoPhage S.A. is proud to announce that it has recently been granted with the #COTEC Innovative Status 2021

Leonor Martins is doing a #summerinternship at Technophage through the #InstitutoSuperiorTécnico Summer Internships 2021 program. It is with great satisfaction that Technophage collaborates with #IST and contributes to the development of future Engineers! #Training

We are proud to announce that a potential new therapeutic #antibody for the treatment of #COVID-19 has been identified. The candidate antibody was born from a #research project, having obtained promising neutralization results, even against the most recent strains of the #virus.

Last week #TechnoPhage held its Annual Meeting where the CEO, Miguel Garcia, took the opportunity to speak to the collaborators about recent achievements and future perspectives and goals. Go #team!

#TechnoPhage is proud to announce that the first part of the Phase I/IIa Clinical Trial with TP-102 (#REVERSE study) has been completed. There were no adverse effects associated with the product, according to the Safety Committee. The second part of study is ongoing. #phages

Today, we are at #PhageFuturesEurope2021 taking place in Brussels. We'll be presenting our latest findings in phage therapy against chronic wound infections and discussing the challenges of phage delivery. Check out the event here: rb.gy/sdz1vy

Welcome to our #Viruses of Microbes meeting countdown! We start with Joana Azeredo and Madalena Pimentel organizers of @Vom2020 talking about the site of the meeting, the beautiful city of #Guimarães, #Portugal. Coming up short #science clips by our speakers!

This year #virusesofmicrobes will take place in #Guimarães. The organizing committee composed by Joana Azeredo and Madalena Pimentel will be welcoming you to #Portugal in 2022. Join #technophage team at #vom next week. See you there.

#technophage has been featured in Labiotech.eu as one of the 15 biotech companies in #Portugal you should know. labiotech.eu/best-biotech/b…

We're hiring! For more details, please follow the link bellow linkedin.com/jobs/view/3190…

#TechnoPhage, #LxBio, #FFUL and #vectorB2B announce signing of a #PRR Grant Agreement with the Portuguese Government as #BioHub consortium

TechnoPhage S.A. is proud to announce spin-off of T-Oncology AG. The new company is incorporated in Steinhausen (ZG), Switzerland, and will focus on the development of #ADCs, based on the proprietary small domain #antibodies platform, for the treatment of #cancer.

Chronic Prosthetic joint #infection by #Pseudomonas aeruginosa successfully treated after personalized #phage & meropenem combination #therapy . Case study in Italy coordinated by Mariagrazia Di Luca , #publication in Open Forum Infectious Diseases : bit.ly/3X5f3Jh #biofilm #microbiology #AMR